Array comparative genomic hybridization (aCGH) has led to an increased detection of causal chromosomal imbalances in individuals with congenital heart defects (CHD). The introduction of aCGH as a diagnostic tool in a clinical cardiogenetic setting entails numerous challenges. Based on our own experience as well as those of others described in the literature, we outline the state of the art and attempt to answer a number of outstanding questions such as the detection frequency of causal imbalances in different patient populations, the added value of higher-resolution arrays, and the existence of predictive factors in syndromic cases. We introduce a step-by-step approach for clinical interpretation of copy number variants (CNV) detected in CHD, which is primarily based on gene content and overlap with known chromosomal syndromes, rather than on CNV inheritance and size. Based on this algorithm, we have reclassified the detected aberrations in aCGH studies for their causality for syndromic and non-syndromic CHD. From this literature overview, supplemented with own investigations in a cohort of 46 sporadic patients with severe non-syndromic CHD, it seems clear that the frequency of causal CNVs in non-syndromic CHD populations is lower than that in syndromic CNV populations (3.6 vs. 19%). Moreover, causal CNVs in non-syndromic CHD mostly involve imbalances with a moderate effect size and reduced penetrance, whereas the majority of causal imbalances in syndromic CHD consistently affects human development and significantly reduces reproductive fitness.

Keywords:
Algorithm, Array CGH, Congenital heart defects (CHD), Copy number variation (CNV), Non-syndromic CHD
1.
Barriot R, Breckpot J, Thienpont B, Brohee S, Van Vooren S, et al: Collaboratively charting the gene-to-phenotype network of human congenital heart defects. Genome Med 2:16 (2010).
2.
Bleyl SB, Saijoh Y, Bax NA, Gittenberger-de Groot AC, Wisse LJ, et al: Dysregulation of the PDGFRA gene causes inflow tract anomalies including TAPVR: integrating evidence from human genetics and model organisms. Hum Mol Genet 19:1286–1301 (2010).
3.
Boone PM, Bacino CA, Shaw CA, Eng PA, Hixson PM, et al: Detection of clinically relevant exonic copy-number changes by array CGH. Hum Mutat 31:1326–1342 (2010).
4.
Breckpot J, Takiyama Y, Thienpont B, Van Vooren S, Vermeesch JR, et al: A novel genomic disorder: a deletion of the SACS gene leading to spastic ataxia of Charlevoix-Saguenay. Eur J Hum Genet 16:1050–1054 (2008).
5.
Breckpot J, Thienpont B, Peeters H, de Ravel T, Singer A, et al: Array comparative genomic hybridization as a diagnostic tool for syndromic heart defects. J Pediatr 156:810–817 (2010).
6.
Bruneau BG: The developmental genetics of congenital heart disease. Nature 451:943–948 (2008).
7.
Brunetti-Pierri N, Berg JS, Scaglia F, Belmont J, Bacino CA, et al: Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 40:1466–1471 (2008).
8.
Christiansen J, Dyck JD, Elyas BG, Lilley M, Bamforth JS, et al: Chromosome 1q21.1 contiguous gene deletion is associated with congenital heart disease. Circ Res 94:1429–1435 (2004).
9.
de Vries BB, White SM, Knight SJ, Regan R, Homfray T, et al: Clinical studies on submicroscopic subtelomeric rearrangements: a checklist. J Med Genet 38:145–150 (2001).
10.
Erdogan F, Larsen LA, Zhang L, Tümer Z, Tommerup N, et al: High frequency of submicroscopic genomic aberrations detected by tiling path array comparative genome hybridisation in patients with isolated congenital heart disease. J Med Genet 45:704–709 (2008)
11.
Fakhro KA, Choi M, Ware SM, Belmont JW, Towbin JA, et al: Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. Proc Natl Acad Sci USA 108:2915–2920 (2010).
12.
Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, et al: Mutations in NOTCH1 cause aortic valve disease. Nature 437:270–274 (2005).
13.
Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, et al: De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet 41:931–935 (2009).
14.
Gu H, Smith FC, Taffet SM, Delmar M: High incidence of cardiac malformations in connexin40-deficient mice. Circ Res 93:201–206 (2003).
15.
Hennekam RC: A newborn with unusual morphology: some practical aspects. Semin Fetal Neonatal Med 16:109–113 (2011).
16.
Itsara A, Wu H, Smith JD, Nickerson DA, Romieu I, et al: De novo rates and selection of large copy number variation. Genome Res 20:1469–1481 (2010).
17.
Jakobsson M, Scholz SW, Scheet P, Gibbs JR, VanLiere JM, et al: Genotype, haplotype and copy-number variation in worldwide human populations. Nature 451:998–1003 (2008).
18.
Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, et al: Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115:2995–3014 (2007).
19.
Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, et al: Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet 79:370–377 (2006).
20.
Koolen DA, Pfundt R, de Leeuw N, Hehir-Kwa JY, Nillesen WM, et al: Genomic microarrays in mental retardation: a practical workflow for diagnostic applications. Hum Mutat 30:283–292 (2009).
21.
Krepischi-Santos AC, Vianna-Morgante AM, Jehee FS, Passos-Bueno MR, Knijnenburg J, et al: Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations. Cytogenet Genome Res 115:254–261 (2006).
22.
Kurnit DM, Layton WM, Matthysse S: Genetics, chance, and morphogenesis. Am J Hum Genet 41:979–995 (1987).
23.
Lee C, Iafrate AJ, Brothman AR: Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. Nat Genet 39: S48–S54 (2007).
24.
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al: Finding the missing heritability of complex diseases. Nature 461:747–753 (2009).
25.
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al: Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82:477–488 (2008).
26.
Meberg A, Hals J, Thaulow E: Congenital heart defects – chromosomal anomalies, syndromes and extracardiac malformations. Acta Paediatr 96:1142–1145 (2007).
27.
Mefford HC, Sharp AJ, Baker C, Itsara A, Jiang Z, et al: Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 359:1685–1699 (2008).
28.
Oyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M: Recurrence of congenital heart defects in families. Circulation 120:295–301 (2009).
29.
Portnoi MF: Microduplication 22q11.2: a new chromosomal syndrome. Eur J Med Genet 52:88–93 (2009).
30.
Rauch R, Hofbeck M, Zweier C, Koch A, Zink S, et al: Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot. J Med Genet 47:321–331 (2010).
31.
Richards AA, Santos LJ, Nichols HA, Crider BP, Elder FF, et al: Cryptic chromosomal abnormalities identified in children with congenital heart disease. Pediatr Res 64:358–363 (2008).
32.
Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al: Strong association of de novo copy number mutations with autism. Science 316:445–449 (2007).
33.
Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, et al: Large recurrent microdeletions associated with schizophrenia. Nature 455:232–236 (2008).
34.
Theveniau-Ruissy M, Dandonneau M, Mesbah K, Ghez O, Mattei MG, et al: The del22q11.2 candidate gene TBX1 controls regional outflow tract identity and coronary artery patterning. Circ Res 103:142–148 (2008).
35.
Thienpont B, Mertens L, de Ravel T, Eyskens B, Boshoff D, et al: Submicroscopic chromosomal imbalances detected by array-CGH are a frequent cause of congenital heart defects in selected patients. Eur Heart J 28:2778–2784 (2007a).
36.
Thienpont B, de Ravel T, Van Esch H, Van Schoubroeck D, Moerman P, et al: Partial duplications of the ATRX gene cause the ATR-X syndrome. Eur J Hum Genet 15:1094–1097 (2007b).
37.
Thienpont B, Zhang L, Postma AV, Breckpot J, Tranchevent LC, et al: Haploinsufficiency of TAB2 causes congenital heart defects in humans. Am J Hum Genet 86:839–849 (2010).
38.
Vermeesch JR, Balikova I, Schrander-Stumpel C, Fryns JP, Devriendt K: The causality of de novo copy number variants is overestimated. Eur J Hum Genet [Epub ahead of print] (2011).
39.
Vissers LE, van Ravenswaaij CM, Admiraal R, Hurst JA, de Vries BB, et al: Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. Nat Genet 36:955–957 (2004).
40.
Wessels MW, Willems PJ: Genetic factors in non-syndromic congenital heart malformations. Clin Genet 78:103–123 (2010).
41.
Wincent J, Anderlid BM, Lagerberg M, Nordenskjold M, Schoumans J: High-resolution molecular karyotyping in patients with developmental delay and/or multiple congenital anomalies in a clinical setting. Clin Genet 79:147–157 (2011).
42.
Yagi H, Furutani Y, Hamada H, Sasaki T, Asakawa S, et al: Role of TBX1 in human del22q11.2 syndrome. Lancet 362:1366–1373 (2003).
43.
Yobb TM, Somerville MJ, Willatt L, Firth HV, Harrison K, et al: Microduplication and triplication of 22q11.2: a highly variable syndrome. Am J Hum Genet 76:865–876 (2005).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.